Marinus Pharmaceuticals, Inc.
NASDAQ:MRNS
0.36 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Marinus Pharmaceuticals, Inc. |
Symbool | MRNS |
Munteenheid | USD |
Prijs | 0.359 |
Beurswaarde | 19,775,156 |
Dividendpercentage | 0% |
52-weken bereik | 0.26 - 11.26 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Scott N. Braunstein M.D. |
Website | https://marinuspharma.com |
An error occurred while fetching data.
Over Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)